Physician

Mirela Andrei, M.D.

According to 2025 Medicare claims, Mirela Andrei, M.D. (NPI: 1578875225) practices hematology/oncology in the Spokane-Spokane Valley, WA market, with the plurality of this provider's patient population coming from Spokane, WA. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 99208-1129. Andrei is affiliated with the Kootenai Accountable Care, LLC (ACO ID: A3621), Caravan Collaborative Pathways (ACO ID: A4604), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Andrei's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 624 traditional Medicare patients, billed 109,721 HCPCS/CPT codes, and received $2,463,135 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 792 prescription claims across 152 beneficiaries totaling $2,370,497 in drug costs, led by Jakafi (Ruxolitinib Phosphate). Open Payments data shows 188 records totaling $4,041. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $10,269 to $2,463,135. Similarly, Part D prescription costs have moved sharply higher in recent years, from $160,170 to $2,370,497. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	84	152	$10,269
2017	150	454	$28,053
2018	144	412	$23,861
2019	132	407	$24,071
2020	324	59,347	$1,490,574
2021	501	97,645	$1,964,794
2022	594	116,783	$2,906,769
2023	660	123,143	$3,079,142
2024	624	109,721	$2,463,135

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	27	84	$160,170
2016	36	79	$85,543
2017	78	286	$245,164
2018	75	333	$437,639
2019	74	330	$445,990
2020	106	417	$407,492
2021	122	709	$2,393,852
2022	123	730	$2,107,984
2023	130	696	$1,452,738
2024	152	792	$2,370,497

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	91	134	$97
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	460	1,194	$67
80053	Blood test, comprehensive group of blood chemicals	249	488	$10
36415	Insertion of needle into vein for collection of blood sample	291	622	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	364	1,121	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	39	1,170	$477,935
Revlimid	Lenalidomide	29	812	$337,163
Ibrance	Palbociclib	16	448	$254,438
Verzenio	Abemaciclib	16	448	$243,105
Calquence	Acalabrutinib Maleate	14	420	$129,244

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	188	$4,041	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mirela Andrei, M.D.?

Tedicare shows public-source Medicare data for Mirela Andrei, M.D. (NPI 1578875225), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mirela Andrei, M.D. have ACO affiliation data?

Mirela Andrei, M.D. is shown with ACO affiliation data for Kootenai Accountable Care, LLC (MSSP, ACO ID A3621), Caravan Collaborative Pathways (MSSP, ACO ID A4604), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Mirela Andrei, M.D.?

Mirela Andrei, M.D. is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Mirela Andrei, M.D. have Open Payments data?

Mirela Andrei, M.D. has 188 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.